Skip to main content

Advertisement

SpringerLink
Log in

The pigment epithelium-derived factor (PEDF): an important potential therapeutic agent for infantile hemangioma

  • Original Paper
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

In previous studies, the expression and the role of proangiogenic factors in infantile hemangiomas have been well studied. However, the role of angiogenic inhibitors has been revealed rarely. The expression of PEDF, as the strongest and safe endogenous inhibitor, is still unrecognized until the current study. In order to investigate the expression and significance of the pigment epithelium-derived factor (PEDF) in the proliferating and regressing phases of infantile hemangiomas, the expression of PEDF, VEGF, Ki-67, and CD34 protein in hemangioma tissues was examined with immunohistochemical polymer HRP method in 42 cases during the proliferative phase, 40 cases during the regressing phase, and 11 cases of non-involuting congenital hemangiomas (NICHs). Meanwhile, the mRNA expression of these factors was detected with quantitative realtime RT-PCR. We found the protein and mRNA expression of PEDF in regressing phase was significantly higher than those in proliferative phase and NICHs (P < 0.001), while the protein and mRNA expression of VEGF were much lower (P < 0.001). The microvessel density (MVD), Ki-67 changes, and the expression of PEDF and VEGF were found significantly correlated. These results indicated that the reduction of VEGF and increase in PEDF are causative to the evolution of infantile hemangioma. PEDF may play a key role in the spontaneous regression of infantile hemangioma and may become an important potential therapeutic agent for infantile hemangioma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Akhavan A (2010) Current treatments for infantile hemangiomas. J Drugs Dermatol 9:176–180

    PubMed  Google Scholar 

  2. Alcantara MB, Dass CR (2013) Regulation of MT1-MMP and MMP-2 by the serpin PEDF: a promising new target for metastatic cancer. Cell Physiol Biochem 31:487–494

    Article  CAS  PubMed  Google Scholar 

  3. Becerra SP (2006) Focus on molecules: pigment epithelium-derived factor (PEDF). Exp Eye Res 82:739–740

    Article  PubMed  Google Scholar 

  4. Belkacemi L, Zhang SX (2016) Anti-tumor effects of pigment epithelium—derived factor (PEDF): implication for cancer therapy. A mini-review. J Exp Clin Cancer Res 35(1):1–4

    Article  Google Scholar 

  5. Boscolo E, Bischoff J (2009) Vasculogenesis in infantile hemangioma. Angiogenesis 12:197–207

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Bruckner AL, Frieden IJ (2003) Hemangiomas of infancy. J Am Acad Dermatol 48:477–493

    Article  PubMed  Google Scholar 

  7. Cai J, Parr C, Watkins G et al (2006) Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin Cancer Res 12:3510–3517

    Article  CAS  PubMed  Google Scholar 

  8. Cheung LW, Au SC, Cheung AN et al (2006) Pigment epithelium-derived factor is estrogen sensitive and inhibits the growth of human ovarian cancer and ovarian surface epithelial cells. Endocrinology 147:4179–4191

    Article  CAS  PubMed  Google Scholar 

  9. Dawson D, Volpert O, Gillis W et al (1999) Pigment epithelium derived factor: a potent inhibitor of angiogenesis. Science 285:245–248

    Article  CAS  PubMed  Google Scholar 

  10. Demestre M, Terzi MY, Mautner V et al (2013) Effects of pigment epithelium derived factor (PEDF) on malignant peripheral nerve sheath tumours (MPNSTs). J Neurooncol 115:391–399

    Article  CAS  PubMed  Google Scholar 

  11. Drolet BA, Swanson EA, Frieden IJ et al (2008) Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr 153:712–715

    Article  PubMed  Google Scholar 

  12. Eivazi B, Ardelean M, Baumler W et al (2009) Update on haemangiomas and vascular malformations of the head and neck. Eur Arch Otorhinolaryngol 266:187–197

    Article  PubMed  Google Scholar 

  13. Ek ET, Dass CR, Choong PF (2006) Pigment epithelium-derived factor: a multimodal tumor inhibitor. Mol Cancer Ther 57:1641

    Article  Google Scholar 

  14. Fernandez-Garcia NI, Volpert OV, Jimenez B (2007) Pigment epithelium-derived factor as a multifunctional antitumor factor. J Mol Med 85:15–22

    Article  CAS  PubMed  Google Scholar 

  15. Gaudreault J, Shiu V, Bricarello A et al (2005) Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics. Int J Toxicol 24:357–363

    Article  CAS  PubMed  Google Scholar 

  16. Guan M, Yam HF, Su B et al (2003) Loss of pigment epithelium derived factor expression in glioma progression. J Clin Pathol 56:277–282

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Guo T, Gu C, Li B (2012) PEDF inhibits growth and invasiveness of endometrial cancer cells in vitro. Panminerva Med 54(4):299–304

    CAS  PubMed  Google Scholar 

  18. Halin S, Wikstrom P, Rudolfsson SH et al (2004) Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. Cancer Res 64:5664–5671

    Article  CAS  PubMed  Google Scholar 

  19. Haurigot V, Villacampa P, Ribera A et al (2012) Long-term retinal PEDF overexpression prevents neovascularization in a murine adult model of retinopathy. PLoS One 7:e41511

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hoshina D, Abe R, Yamagishi SI et al (2010) The role of PEDF in tumor growth and metastasis. Curr Mol Med 10:292–295

    Article  CAS  PubMed  Google Scholar 

  21. Ide H, Yamagishi S, Lu Y (2015) Circulating pigment epithelium- derived factor (PEDF) is associated with pathological grade of prostate cancer. Anticancer Res 35(3):1703–1708

    CAS  PubMed  Google Scholar 

  22. Janmohamed SR, Madern GC, de Laat PC (2015) Therapy of infantile haemangioma–history and current state. Eur J Pediatr 174(2):259–266

    Article  PubMed  Google Scholar 

  23. Jinnin M, Ishihara T, Boye E et al (2010) Recent progress in studies of infantile hemangioma. J Dermatol 37(4):283–298

    Article  PubMed  Google Scholar 

  24. Kubicka-Trzaska A, Wilanska J, Romanowska-Dixon B et al (2012) Circulating antiretinal antibodies predict the outcome of anti-VEGF therapy in patients with exudative age-related macular degeneration. Acta phthalmol 90:e21–e24

    Article  CAS  Google Scholar 

  25. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T et al (2008) Propranolol for severe hemangiomas of infancy. N Engl J Med. 358(24): 2649–2651

    Article  PubMed  Google Scholar 

  26. MacIsaac ZM, Nayar HS, Gehris R (2016) Treatment for infantile hemangiomas: selection criteria, safety, and outcomes using oral propranolol during the early phase of propranolol use for hemangiomas. J Craniofac Surg 27(1):159–162

    Article  PubMed  Google Scholar 

  27. Manley PW, Martiny-Baron G, Schlaeppi JM et al (2002) Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs 11:1715–1736

    Article  CAS  PubMed  Google Scholar 

  28. Matsumoto K, Ishikawa H, Nishimura D et al (2004) Antiangiogenic property of pigment epithelium—derived factor in hepatocellular carcinoma. Hepatology 40:252–259

    Article  CAS  PubMed  Google Scholar 

  29. Mei LT, Peter FM, Crispin RD et al (2010) Anti-chondrosarcoma effects of PEDF mediated via molecules important to apoptosis, cell cycling, adhesion and invasion. Biochem Biophys Res Commun 398:613–618

    Article  Google Scholar 

  30. Mori K, Gehtbach P, Yammnoto S et al (2002) AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 43:1994–2000

    PubMed  Google Scholar 

  31. Neri I, Balestri R, Patrizi A et al (2012) Hemangiomas: new insight and medical treatment. Dermatol Ther 25:322–334

    Article  PubMed  Google Scholar 

  32. Rosen LS (2002) Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 9(2 Suppl):36–44

    PubMed  Google Scholar 

  33. Stellmach V, Crawford SE, Zhou W et al (2001) Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA 98:2593–2597

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Takanori M, Yuri N, Sayaka M et al (2012) PEDF-derived peptide inhibits corneal angiogenesis by suppressing VEGF expression. Microvasc Res 84:105–108

    Article  Google Scholar 

  35. Takenak K, Yamagishi S, Jinnouchi Y, et al. (2005) Pigment epithelium-derived factor(PEDF) induced apoptosis and inhibition of vascular endothelial growth factor(VEGF) expression in MG63 human osteosarcoma cells. Life Sci 77:3231–3241

    Article  Google Scholar 

  36. Wang Q, Zhang Z, Ding T et al (2013) Mesenchymal stem cells overexpressing PEDF decreased the angiogenesis of gliomas. Biosci Rep 33:e00019

    Article  PubMed  PubMed Central  Google Scholar 

  37. Wu QJ, Gong CY, Luo ST et al (2012) AAV-mediated human PEDF inhibits tumor growth and metastasis in murine colorectal peritoneal carcinomatosis model. BMC Cancer 12:129

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Yang H, Cheng R, Liu G et al (2009) PEDF inhibits growth of retinoblastoma by anti-angiogenic activity. J. Cancer Sci 100:2419–2425

    Article  CAS  PubMed  Google Scholar 

  39. Yang LP, Cheng P, Peng XC et al (2009) Anti-tumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16-F10 melanoma. J Exp Clin Cancer Res 28:75

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Zhang SX, Wang JJ, Gao G et al (2006) Pigment epithelium- derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 37:1–12

    Article  PubMed  Google Scholar 

  41. Zheng D, Chen H, Davids J et al (2013) Serpins for diagnosis and therapy in cancer. Cardiovasc Hematol Disord Drug Targets 13:123–132

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Sincere thanks are due to Fangmeng Fu for his valuable academic suggestion and his warm encouragement, and to Yuanjing Chen for his assistance with the experiments.

Author information

Authors and Affiliations

  1. Plastic Surgery Department of Affiliated Fujian Union Hospital of Fujian Medical University, No.29, Xinquan Road, Fuzhou, 350001, Fujian, China

    Ming Li, Zhihui Guo, Yide Xie, Yakuan Zhou, Chenghong Jiang & Xiaosong Chen

  2. Xiamen Eye Centre of Xiamen University, Xiamen, 361000, Fujian, China

    Yanru Chen

Authors
  1. Ming Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yanru Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhihui Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yide Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yakuan Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chenghong Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaosong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhihui Guo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

This research was supported by Fujian Youth Foundation of Fujian Health Department (2013-1-28) and the National Natural Science Foundation of China (81470125).

Ethical approval

All procedures performed in the study involving human participants were in accordance with the ethical standards of the Bioethical Committee of Affiliated Fujian Union Hospital of Fujian Medical University and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from parents of all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, M., Chen, Y., Guo, Z. et al. The pigment epithelium-derived factor (PEDF): an important potential therapeutic agent for infantile hemangioma. Arch Dermatol Res 309, 169–178 (2017). https://doi.org/10.1007/s00403-017-1716-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-017-1716-5

Keywords

Search

Navigation